SpyGlass Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	238.9	96.36	16.27	15.85
Short-Term Investments	12.1	11.08	-	24.47
Cash & Short-Term Investments	251	107.44	16.27	40.32
Cash Growth	1442.92%	560.41%	-59.65%	-
Other Receivables	0.65	0.43	0.42	0.12
Total Trade Receivables	0.65	0.43	0.42	0.12
Other Current Assets	1.71	0.9	0.72	0.18
Total Current Assets	253.36	108.77	17.41	40.61
Net Property, Plant & Equipment	4.24	3.89	5.46	0.45
Other Long-Term Assets	0.79	3.21	0.45	0.09
Total Assets	258.39	115.87	23.32	41.15
Accounts Payable	3.51	2.7	1.98	0.64
Accrued Expenses	0.88	2.18	1.28	0.61
Current Portion of Leases	-	-	0.44	-
Other Current Liabilities	2.27	3.71	4.09	0.34
Total Current Liabilities	6.67	8.58	7.79	1.59
Long-Term Leases	1.61	1.58	3.46	-
Total Long-Term Liabilities	1.61	1.58	3.46	-
Total Liabilities	8.27	10.17	11.25	1.59
Common Stock	-	-	-	0
Additional Paid-in Capital	368.66	5.89	4.39	2.71
Retained Earnings	-118.55	-104.73	-64.86	-35.7
Total Common Shareholders' Equity	250.11	-98.84	-60.47	-32.99
Minority Interest	-	-	-	72.55
Shareholders' Equity	250.11	-98.84	-60.47	39.56
Total Liabilities & Equity	258.39	115.87	23.32	41.15
Total Debt	1.61	1.58	3.9	0
Net Cash (Debt)	249.4	105.85	12.37	40.32
Net Cash Growth	135.60%	755.66%	-69.31%	-
Net Cash Per Share	7.46	47.74	6.92	23.20
Book Value	250.11	-98.84	-60.47	-32.99
Book Value Per Share	7.48	-44.58	-33.82	-18.98
Tangible Book Value	250.11	-98.84	-60.47	-32.99
Tangible Book Value Per Share	7.48	-44.58	-33.82	-18.98

SEC Filings: 10-K · 10-Q